癌症研究
间充质干细胞
CD8型
肿瘤坏死因子α
免疫疗法
肿瘤微环境
CXCL9型
免疫系统
细胞生物学
免疫学
生物
趋化因子
CXCL10型
作者
Pan Yin,Liming Gui,Caihong Wang,Jingjing Yan,Min Liu,Lu Ji,You Wang,Bin Ma,Wei‐Qiang Gao
标识
DOI:10.1016/j.ymthe.2020.08.005
摘要
Major obstacles in immunotherapies include toxicities associated with systemic administration of therapeutic agents, as well as low tumor lymphocyte infiltration that hampers the efficacies. In this study, we report a mesenchymal stem cell (MSC)-based immunotherapeutic strategy in which MSCs specifically deliver T/natural killer (NK) cell-targeting chemokine CXCL9 and immunostimulatory factor OX40 ligand (OX40L)/tumor necrosis factor superfamily member 4 (TNFSF4) to tumor sites in syngeneic subcutaneous and azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced spontaneous colon cancer mouse models. This approach generated potent local antitumor immunity by increasing the ratios of tumor-infiltrating CD8 + T and NK cells and production of antitumor cytokines and cytolytic proteins in the tumor microenvironment. Moreover, it improved the efficacy of programmed death-1 (PD-1) blockade in a syngeneic mouse model and significantly suppressed the growth of major histocompatibility complex class I (MHC class I)-deficient tumors. Our MSC-based immunotherapeutic strategy simultaneously recruits and activates immune effector cells at the tumor site, thus overcoming the problems with toxicities of systemic therapeutic agents and low lymphocyte infiltration of solid tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI